Implementing TMB measurement in clinical practice: considerations on assay requirements
Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours. However, there is a need for the development of predictive biomarkers that identify patients who are most likely to respond to immunotherapy. Com...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-02-01
|
| Series: | ESMO Open |
| Online Access: | https://esmoopen.bmj.com/content/4/1/e000442.full |